News
1don MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...
Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...
Eli Lilly will soon bring a pill version to the market, with a version expected to debut at a lower price than injectable ...
Novo Nordisk announces a leadership transition as Lars Fruergaard Jørgensen welcomes new CEO Doug Doustdar. Doustdar aims to ...
Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. US law bars pharmacies from ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Facing a $70 billion market loss, Novo Nordisk appointed Maziar Mike Doustdar as its new CEO to navigate intensifying ...
The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...
It’s no secret that Ozempic isn’t going anywhere, but the weight loss drug category does seem to be rapidly evolving. According to J.P. Morgan Research, up to 30 million people could be on a ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback